Tigecycline Omadacycline Eravacycline: Selection Guide
Tigecycline omadacycline eravacycline are three tetracycline derivatives but they are not interchangeable. Omadacycline is the choice for community infection and for stepping down from IV to oral. Tigecycline reaches tissue well but blood and urine levels stay low, so it is not the default pick for sepsis or urinary infection. Eravacycline has the strongest evidence for complicated intra-abdominal infection. Choose by infection site, resistance risk, and whether oral step-down is needed.
The three drugs at a glance
The three drugs tigecycline omadacycline eravacycline each hold a distinct clinical position even though all are tetracycline derivatives.
- Omadacycline: community-acquired infection and IV-to-oral step-down. It is the only one of the three with an oral tablet. After IV loading it can switch to oral 300 mg once daily.
- Tigecycline: high tissue concentration but low blood and urine concentration. Standard 50 mg every 12 hours can underexpose the bloodstream, urine, and ventilator-associated pneumonia.
- Eravacycline: strongest evidence for complicated intra-abdominal infection. IV only, given as 1 mg/kg every 12 hours infused over about 60 minutes.
Approved uses, formulations, and core doses
Doses below are based on current domestic labeling. Guideline recommendations that go beyond labeling are flagged separately and should not be confused with the approved indication.
Drug | Approved indication | Core dose and course | Guideline position in one line |
Tigecycline | Complicated intra-abdominal infection, complicated skin and soft-tissue infection, community-acquired pneumonia; IV only | Loading 100 mg, then 50 mg every 12 hours. Severe resistant organism high-dose regimen: loading 200 mg, then 100 mg every 12 hours. Intra-abdominal course 5 to 14 days | Good tissue levels, but standard-dose monotherapy not suited to bloodstream, urine, or HAP/VAP; SIS 2024 opposes empiric use for intra-abdominal infection |
Omadacycline | Adult community-acquired bacterial pneumonia and acute bacterial skin and skin-structure infection; IV and oral tablet | Day 1: 200 mg IV over 60 minutes, or 100 mg IV over 30 minutes twice; maintenance 100 mg IV every 24 hours or 300 mg oral once daily. Course 7 to 14 days | Community infection and IV-to-oral step-down; IDSA 2024 does not recommend for CRAB |
Eravacycline | Adult complicated intra-abdominal infection; IV only | 1 mg/kg every 12 hours, IV infusion about 60 minutes; course 4 to 14 days. Strong CYP3A inducer: 1.5 mg/kg every 12 hours; Child-Pugh C from day 2: once daily | SIS 2024 intra-abdominal empiric therapy 1A; IDSA 2024 for non-bloodstream non-urinary CRE and selected CRAB |
The point most easily missed: none of the three works reliably against Pseudomonas aeruginosa. If intra-abdominal infection needs Pseudomonas cover, add an anti-pseudomonal beta-lactam or another active drug. Do not skip this step just because the drug looks broad spectrum.
Choose by infection site: abdomen, lung, skin, blood, urine
Deciding among tigecycline omadacycline eravacycline starts with the infection site, then resistance and dosing.
Abdominal infection: eravacycline has the strongest evidence, tigecycline is not first-line empiric
The 2024 SIS intra-abdominal infection guideline lists eravacycline as 1A empiric antibacterial therapy, with 2C for high-risk patients because of broader spectrum. The same guideline opposes tigecycline for empiric treatment of low-risk and high-risk patients (1-B) based on all-cause mortality and serious adverse-event signals. Support comes from two phase III randomized trials showing eravacycline non-inferior to ertapenem and meropenem.
Domestic expert consensus agrees: for CRE or CRAB intra-abdominal infection, tigecycline can be one combination option, while eravacycline has higher clinical efficacy and better tolerability for common pathogens. The 2025 ESBL-E expert consensus notes tigecycline and eravacycline have stronger in-vitro activity against ESBL-E than omadacycline, but tigecycline is not recommended for ESBL-E bloodstream or urinary infection.
In practice: for suspected ESBL-producing Enterobacterales or resistant Gram-negative cIAI, prioritize eravacycline or a beta-lactam/beta-lactamase inhibitor. Use tigecycline only as targeted therapy or in a combination regimen after confirming susceptibility, assessing the infection site, and weighing mortality risk: not as "start it first."
Lung infection: community-acquired and ventilator-associated are two different questions
Community-acquired pneumonia is the approved setting for omadacycline. One phase III trial showed omadacycline similar to levofloxacin in higher-mortality CAP patients, and it covers atypical pathogens. When oral step-down is needed after discharge, omadacycline's matching IV and oral indication is a clear advantage.
HAP/VAP is the opposite. Tigecycline labeling carries a signal of lower cure and higher mortality for VAP. Domestic 2023 consensus considers standard-dose monotherapy insufficient for severe HAP; high-dose combination may be considered for severe HAP but this is off-label and needs internalfiling. IDSA 2024 favors sulbactam-containing regimens for CRAB pneumonia and prefers minocycline over tigecycline; eravacycline is considered only when minocycline and tigecycline are ineffective, not tolerated, or unavailable; omadacycline is not recommended for CRAB.
Do not equate "high tissue concentration" with "suitable for pneumonia." Consider acquisition setting, pathogen, MIC, bacteremia status, and dose together.
Skin and soft-tissue infection: omadacycline's oral step-down is most convenient
Omadacycline is approved for acute bacterial skin and skin-structure infection, covering MRSA, streptococci, enterococci, and some Gram-negatives. Domestic 2023 consensus lists omadacycline as an oral option covering MRSA, and IV options including omadacycline and tigecycline, with a usual course of 7 to 14 days. Eravacycline has no skin infection indication and should not be extrapolated routinely.
Bloodstream and urinary infection: use all three with restraint
Tetracyclines spread widely into tissue but reach blood in limited amounts. Domestic consensus: CRE or CRAB bloodstream infection should not use tetracyclines as first choice; without alternatives they may be combined. Eravacycline and omadacycline are not recommended due to lack of clinical data. For complicated urinary infection and urosepsis, consider tigecycline only when no better option, combined with a drug that reaches high urine concentration, for at least 10 to 14 days.
When you see bloodstream infection, urinary infection, or bacteremia, put these three cards back and rebuild the regimen from beta-lactams, polymyxins, or other high-exposure drugs.
Resistance scenarios: ESBL-E, CRE, CRAB, and Stenotrophomonas
Guideline strength depends on the pathogen and infection site together. Do not discuss "resistant bacteria" in isolation. Matching tigecycline omadacycline eravacycline to the pathogen and site determines which card to play.
Scenario | ESBL-E | CRE | CRAB |
Activity ranking | Tigecycline and eravacycline stronger than omadacycline | New beta-lactams first; tetracyclines as alternatives | Sulbactam-containing regimen first |
Tigecycline | Effective for cIAI; not for bloodstream or urinary | High-dose combination for severe cases; watch MIC | Minocycline preferred; tigecycline high-dose combination |
Eravacycline | Approved only for cIAI; other infection evidence limited | Alternative for non-bloodstream non-urinary sites | Only when other drugs unavailable; limited data |
Omadacycline | Weaker in-vitro activity | Not recommended | Not recommended |
ESBL-E: activity differs, and the site limit matters more. The 2025 ESBL-E consensus states tigecycline and eravacycline have stronger activity against ESBL-E, omadacycline weaker; tigecycline is effective for ESBL-E intra-abdominal infection but, because of low standard-dose blood concentration and low urinary excretion, is not recommended for bloodstream or urinary infection; eravacycline is approved only for cIAI.
CRE: new beta-lactam/beta-lactamase inhibitors first. IDSA 2024: for KPC or OXA-48, prioritize new beta-lactam/beta-lactamase inhibitor; when beta-lactams are ineffective, not tolerated, or unavailable, tigecycline and eravacycline are alternatives for abdomen, skin, bone, and respiratory infections. Tigecycline should use high dose and watch MIC. Eravacycline activity is not affected by carbapenemase type but is not advised for bloodstream monotherapy. Domestic hematology-oncology CRE consensus lists meropenem plus colistin or eravacycline or tigecycline as optional combinations in severe scenarios, emphasizing enzyme testing and de-escalation after 2 to 4 days based on microbiology. This is a combination position, not monotherapy first choice.
CRAB: do not make tetracyclines the mainstay. IDSA 2024 prefers sulbactam-containing regimens, such as sulbactam-durlobactam plus a carbapenem, or high-dose ampicillin-sulbactam plus at least one other active drug, and does not recommend omadacycline for CRAB. Minocycline (200 mg every 12 hours) has more experience and CLSI breakpoints; tigecycline needs high dose (loading 200 mg, then 100 mg every 12 hours) plus combination, and efficacy may be limited when MIC above 1 mg/L. Eravacycline MIC is usually 2 to 8 times lower than tigecycline but clinical data are scarce. IDSA cites a 93-patient CRAB pneumonia observation: eravacycline vs control, longer ventilation (11 vs 7 days), higher 30-day mortality (33% vs 15%); four CRAB bloodstream patients on eravacycline all died. So use eravacycline only when other drugs have no activity, are not tolerated, or are unavailable.
Stenotrophomonas: tetracyclines have a better fit elsewhere. Domestic 2023 consensus lists minocycline, doxycycline, or tigecycline as options with limited experience; severe, mixed, or resistant infection needs combination. IDSA 2024 favors ceftazidime-avibactam, ceftazidime-avibactam plus aztreonam, high-dose minocycline, co-trimoxazole, or levofloxacin combinations. Omadacycline and eravacycline are not the main agents here.
Dose and administration: when to increase or decrease
Situation | Tigecycline | Omadacycline | Eravacycline |
Standard regimen | Loading 100 mg, then 50 mg every 12 hours, IV infusion 30 to 60 minutes | Day 1: 200 mg IV over 60 minutes, or 100 mg IV over 30 minutes twice; maintenance 100 mg IV every 24 hours or 300 mg oral once daily | 1 mg/kg every 12 hours, IV infusion about 60 minutes |
Severe resistant organism | High dose: loading 200 mg, then 100 mg every 12 hours; usually combination, needs internal off-labelfiling | Not for severe resistant Gram-negative; use labeled dose | Not routinely increased; decide by MIC, site, and combination; strong CYP3A inducer: 1.5 mg/kg every 12 hours |
Liver impairment | Child-Pugh A and B no adjustment; Child-Pugh C loading 100 mg, then 25 mg every 12 hours, use with caution | No adjustment for mild to severe liver impairment | Mild to moderate no adjustment; Child-Pugh C day 1 1 mg/kg every 12 hours, from day 2 once daily |
Kidney impairment | No adjustment, including hemodialysis | No adjustment, including hemodialysis | No adjustment |
Oral and interactions | No oral form | Take oral on an empty stomach: no food or drink except water for 4 hours before and 2 hours after; avoid dairy, antacids, and multivitamins for 4 hours; avoid IV lines with calcium-magnesium polyvalent cation solutions | No oral form; avoid strong CYP3A inducers, and if co-used increase to 1.5 mg/kg every 12 hours |
Three common operational errors: using tigecycline 50 mg every 12 hours as an adequate dose for severe resistant organisms; taking omadacycline oral tablets with food or with milk, antacids, or multivitamins, which directly lowers exposure; giving eravacycline with rifampicin but still dosing 1 mg/kg every 12 hours.
Safety and special populations
Each drug has a few key signals to watch.
Tigecycline: red lines | Omadacycline: caution | Eravacycline: caution |
All-cause mortality signal | Nausea, vomiting, infusion-site reaction | GI reactions dominate |
Nausea and vomiting common, worse with high dose | Tooth discoloration and bone growth effect | Child-Pugh C: reduce frequency from day 2 |
Caution with bowel perforation in intra-abdominal infection | Oral must be strictly fasting | Strong CYP3A inducer: increase dose |
Watch liver enzymes and pancreatitis signal | Pregnancy and under 8 years use with caution | Infuse about 60 minutes, no IV push |
VAP: lower cure, higher mortality | No breastfeeding during treatment and 4 days after last dose | Kidney impairment: no dose adjustment |
Tigecycline. Labeling carries a boxed warning for increased all-cause mortality, reason not fully clear, so use only when no suitable alternative exists. VAP patients showed lower cure and higher mortality. Nausea and vomiting are common, more obvious with high dose. Pancreatitis, liver dysfunction, and liver failure have been reported; stop and assess if pancreatitis symptoms appear. Use with caution in intra-abdominal infection with bowel perforation.
Omadacycline. Common nausea, vomiting, infusion-site reactions. Like other tetracyclines, late pregnancy and under-8 use can cause permanent tooth discoloration and reversible bone growth suppression; no breastfeeding during treatment and 4 days after last dose. The strict fasting rule for oral tablets is a hidden adherence barrier: write it into instructions.
Eravacycline. Tolerance is mainly GI reactions. Severe liver impairment needs frequency adjustment. With strong CYP3A inducers such as rifampicin, increase dose. Kidney impairment and dialysis need no adjustment. IV infusion only, no IV push.
Shared. Tetracycline allergy: avoid or use with caution. Pregnancy: generally avoid. Under 8 years: generally avoid. There is no routine skin test, but a plan for severe allergy should be ready before the first dose. Critically ill or severe liver impairment patients may do tigecycline therapeutic drug monitoring where available, using AUC over MIC to judge whether exposure is sufficient.
Four clinical scenarios: from consult to prescription
Scenario 1: 55-year-old, post-appendectomy intra-abdominal infection, pus culture grows ESBL E. coli, hemodynamically stable.
Look at site: abdomen. Look at risk: ESBL-E, possible anaerobic mixed infection. Per SIS 2024, eravacycline can be used for empiric treatment (1A); if susceptibility is available and no beta-lactam works, eravacycline 1 mg/kg every 12 hours is reasonable targeted therapy. Tigecycline is not empiric first choice; if used eventually, base on susceptibility and weigh mortality risk, course 5 to 14 days by clinical response. Do not forget: if Pseudomonas risk exists, add an anti-pseudomonal drug.
Scenario 2: 73-year-old, community-acquired pneumonia, chest X-ray confirmed, cannot exclude mycoplasma or MRSA, needs admission but stable.
This is omadacycline's home ground: CAP indication covers common bacteria and atypical pathogens and covers MRSA risk. Day 1: 200 mg IV over 60 minutes or 100 mg IV over 30 minutes twice; then 100 mg IV every 24 hours or 300 mg oral once daily. Course 7 to 14 days. If switching to oral, write the fasting rule into discharge instructions: no food or drink except water for 4 hours before and 2 hours after; avoid dairy, antacids, and multivitamins for 4 hours.
Scenario 3: ICU, 55 kg, CRE ventilator-associated pneumonia after external ventricular drain, sputum grows CRAB, MIC pending, platelets and liver acceptable.
Build the skeleton per IDSA 2024: sulbactam-containing regimen first; if unavailable, high-dose ampicillin-sulbactam plus at least one other active drug. Among tetracyclines prefer minocycline 200 mg every 12 hours; if unavailable, consider high-dose tigecycline (loading 200 mg, then 100 mg every 12 hours) in combination, and do not expect much when MIC above 1 mg/L. Eravacycline is a restricted fallback here, not "use because MIC is low"; omadacycline is not recommended. Course, nebulization, and rifampicin combination follow local protocol and latest evidence, not North American guidelines copied blindly.
Scenario 4: 3 months post-kidney transplant, CRE bacteremia controlled, then complicated intra-abdominal infection, susceptibility shows eravacycline sensitive.
The site fits, susceptibility supports, and no active bloodstream infection: eravacycline 1 mg/kg every 12 hours can be used; if rifampicin is co-used, change to 1.5 mg/kg every 12 hours. If bacteremia persists, do not make eravacycline the monotherapy mainstay; return to combination and control the infection source. If Pseudomonas risk or bowel perforation coexists, reassess the regimen rather than simply extending the course.
One-page quick reference, common mistakes, and sources
Clinical scene | Priority action | Position of the three | Most common error |
cIAI empiric | Cover Enterobacterales and anaerobes, assess Pseudomonas risk | Eravacycline 1A; tigecycline not empiric | Using tigecycline by old habit as first choice |
CAP or ABSSSI | Start from community pathogens and atypical cover | Omadacycline, IV loading then oral step-down | Using omadacycline for CRAB or severe intra-abdominal infection |
CRE non-blood non-urine | Check enzyme and new beta-lactam availability | Eravacycline or high-dose tigecycline as alternatives | Skipping new beta-lactams and going straight to tetracyclines |
CRAB | Sulbactam-based regimen as backbone, combination | Minocycline better than tigecycline; eravacycline restricted; omadacycline not advised | Judging by MIC number only, ignoring clinical outcomes |
Bloodstream or urinary | Choose a drug with adequate blood or urine exposure, control source | All three not first choice; combine if necessary | Using monotherapy because the report says susceptible |
Child-Pugh C liver | Check dose for each drug | Tigecycline 25 mg every 12 hours; eravacycline once daily from day 2; omadacycline no change | Treating all three by normal kidney-function logic |
Four common mistakes, debunked one by one.
Newer is not always better. Eravacycline has lower in-vitro MIC and stronger SIS evidence, but CRAB pneumonia data are limited with unfavorable observational signals. Guideline strength is a synthesis of pathogen, site, and evidence quality: not a molecular ranking.
Same class does not mean interchangeable. Omadacycline has no abdomen or HAP/VAP indication; eravacycline has no lung or skin indication; tigecycline standard and high dose are two different clinical positions. Re-check labeling and susceptibility before switching.
"Susceptible" on the report does not mean the dose is enough. Tetracyclines are judged by AUC/MIC. When tigecycline MIC is high and infection is in blood or urine, even a susceptible report may mean underexposure.
Guideline recommendation does not equal routine hospital use. High-dose tigecycline for HAP/VAP and eravacycline for lung or bloodstream infection are off-label and need internalfiling and informed consent.
Bottom line: tigecycline omadacycline eravacycline selection
Tigecycline omadacycline eravacycline are three tetracycline derivatives with different positions. Choose by infection site: omadacycline for community infection and IV-to-oral step-down; eravacycline for complicated intra-abdominal infection; tigecycline for tissue-penetrated combinations with caution in bloodstream and urine. None is reliable against Pseudomonas aeruginosa. Match the drug to the site, resistance risk, and dosing rather than using any one as a default broad-spectrum option. Prescribers who memorize tigecycline omadacycline eravacycline as one interchangeable class will repeat the classic errors.
Eight-second pre-prescription checklist
- Is the infection site written clearly? Abdomen, lung, skin, blood, and urine follow different paths.
- Is Pseudomonas risk assessed? None of the three is a reliable answer.
- Is the domestic labeling indication confirmed? A guideline recommendation is not automatically an indication.
- Is the specific MIC value checked? Do not stop at "susceptible."
- Are Child-Pugh liver class and co-medications confirmed?
- Are omadacycline oral fasting instructions written?
- Is the off-label process for high-dose tigecycline completed?
- Is there a reassessment and de-escalation plan at 48 to 72 hours?
Main guidelines and consensus checked
- Multidisciplinary expert consensus on rational use of commonly used tetracycline drugs (2023), led by the Chinese Preventive Medicine Association Hospital Infection Control Branch and the Chinese Pharmacological Society Clinical Pharmacology Branch: 17 expert opinions covering indications, off-label use, special populations, and TDM.
- IDSA. 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: tetracycline positioning for CRE, CRAB, and Stenotrophomonas.
- SIS. Guidelines for Management of Intra-Abdominal Infection: 2024 Update: eravacycline empiric therapy 1A, tigecycline empiric therapy 1-B.
- Expert consensus on response strategy for clinical ESBL-producing Enterobacterales infection (2025), Chinese Journal of Infection Control: in-vitro activity ranking of new tetracyclines against ESBL-E and site limits.
- Expert consensus on diagnosis, treatment and prevention of CRE infection in hematology-oncology patients (2025): positions of eravacycline and tigecycline in severe CRE combination regimens.
Guidelines and consensus checked are editions publicly released before November 2026. Specific doses, indications, and contraindications follow current drug labeling and the hospital antimicrobial stewardship program.
Disclaimer: This article is for medical education and clinical discussion only. It cannot replace drug labeling, the hospital antimicrobial management policy, or the attending physician's individual judgment. Antimicrobial use must combine pathology, susceptibility, infection site, liver and kidney function, and co-medication. Off-label use must follow institutional approval and informed consent.
FAQ
Is omadacycline the only one of the three that can be taken by mouth?
Yes. Omadacycline is the only one of the three with an oral tablet. After IV loading it can switch to oral 300 mg once daily. Tigecycline and eravacycline are IV only.
Can tigecycline be used as monotherapy for bloodstream infection?
No. Tigecycline standard-dose blood concentration is low, so monotherapy for bloodstream infection, urinary infection, or HAP/VAP risks underexposure. Severe resistant cases may use high dose in combination, not monotherapy.
Why is eravacycline preferred for complicated intra-abdominal infection?
SIS 2024 gives eravacycline a 1A empiric recommendation for intra-abdominal infection, and two phase III trials showed non-inferiority to ertapenem and meropenem. Tigecycline is opposed for empiric use due to mortality and adverse-event signals.
Can eravacycline treat lung infection or bloodstream infection?
No approved lung, bloodstream, or urinary indication. IDSA lists it only as a fallback for non-bloodstream non-urinary CRE when minocycline and tigecycline fail. Off-label lung or bloodstream use needsfiling and consent.
Does tigecycline work against carbapenem-resistant Enterobacterales?
It can be an alternative for non-bloodstream non-urinary CRE such as abdomen, skin, bone, and respiratory sites, using high dose and watching MIC. New beta-lactams remain first choice; CRE bloodstream should not use tigecycline alone.
When should the tigecycline dose be increased?
For severe resistant organisms, use loading 200 mg then 100 mg every 12 hours, usually in combination with off-labelfiling. Standard 50 mg every 12 hours is not adequate for severe resistant bloodstream or lung infection.
Does eravacycline interact with rifampicin?
Yes. Rifampicin is a strong CYP3A inducer; co-use requires increasing eravacycline to 1.5 mg/kg every 12 hours. Do not keep 1 mg/kg every 12 hours, or exposure will fall below target.
Is any of the three reliable against Pseudomonas aeruginosa?
None of the three is reliable against Pseudomonas aeruginosa. Cover Pseudomonas with an anti-pseudomonal beta-lactam or another active drug when needed.
Can omadacycline be used for carbapenem-resistant Acinetobacter?
IDSA 2024 does not recommend omadacycline for CRAB. It is not a CRAB treatment option; choose sulbactam-based regimens or other active agents such as minocycline combinations.
What precautions apply to omadacycline oral tablets?
Take on an empty stomach: nothing except water for 4 hours before and 2 hours after; avoid dairy, antacids, and multivitamins for 4 hours. No breastfeeding during treatment and 4 days after the last dose.
Are these drugs safe in pregnancy and young children?
Generally avoid in pregnancy and under 8 years due to tooth discoloration and bone growth effects. Tetracycline allergy requires avoidance or caution. No routine skin test, but prepare for severe allergy.
How should a prescriber choose among the three?
First identify the infection site, then resistance risk, then whether oral step-down is needed. Omadacycline for community infection and step-down; eravacycline for intra-abdominal infection; tigecycline for tissue-penetrated combinations with caution for blood and urine.